Boundless Bio
pathway amplification mediated acquired resistance initial croc inhibitors tan | Boundless Bio
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2024
Slide
44 of 51
Related slides by other companies
AstraZeneca
Results
November 2024
factor inhibitor ophthalmology | AstraZeneca
MAIA Biotechnology
Investor Presentation
July 2023
significant market opportunity | MAIA Biotechnology
Nuvalent
Investor Presentation
October 2022
safety and preliminary clinical activity of a highly selective inhibitor in patients with advanced fusion positive solid tumors cine | Nuvalent
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights